Skip to main content
. 2016 Jun 25;129:319–328. doi: 10.1007/s11060-016-2177-y

Table 1.

Patient demographics

n = 46 patients n %
Age at first diagnosis (years; median, range) 35 (17–54)
Sex (female:male) 25:21 54.3:45.7
IDH1 mutation 38 82.6
Follow-up (months; median, range) 69 (17.5–164.6)
OS (months; median, range) 119.8 (17.5–164.6)
PFS (months; median, range) 45.1 (4.7–164.6)
MPFS (months; median, range) 81.4 (4.7–164.6)
TTR (months; median, range) 40.9 (4.5–164.6)
Progression 26 56.5
Malignant progression 19 41.3
Death 11 23.9
Seizure as first diagnosis 30 65.2
Time from radiographic diagnosis to surgery (months; median, range) 0 (0–91)
KPS pre-op (median, range) 100 (80–100)
KPS post-op (median, range) 100 (70–100)
New permanent neurologic deficits
 None 43 93.5
 Yes 3 6.5
Tumor eloquence 6 13
Tumor side (left:right) 20:26 43.5:56.5
Tumor localization (lobe)
 Frontal 23 50
 Temporal 18 39.1
 Others 5 10.9
Contrast enhancement pre-op 14 30.4
dT2T1 (cm3, median, range) 3.41 (−43.02 to 64.52)
Upfront adjuvant treatment 7 15.2
 Chemotherapy 2
 Radiotherapy 3
 Combined radio-/chemotherapy 2
Complete resection planned 27 58.7
iMRI employed 33 71.7
 Continued resection after iMRI 27 (81.8)
Vol. pre-op (cm3; median, range) 44.23 (0.78–193.04)
Vol. iMRI (cm3; median, range) 4.95 (0–143.94)
 EOR iMRI (%; median, range) 69.5 (13.3–100)
Vol. epMRI (cm3; median, range) 5.32 (0–113.9)
 EOR epMRI (%; median, range) 69.6 (10.9–100)
Vol. follow-up MRI (cm3; median, range) 4.09 (0–167.98)
 EOR follow-up MRI (%; median, range) 90.4 (17.5–100)

OS overall survival, PFS progression-free survival, MPFS malignant progression-free survival, TTR time to re-intervention, KPS Karnofsky Performance Score, Vol (tumor) volume, iMRI intraoperative MRI, epMRI early postoperative MRI, EOR extent of resection, dT2T1 volumetric difference of signal abnormality between preoperative T2-FLAIR sequences and native T1 sequences